- 16 patients surpassed 12-month survival follow-up
- THIO's substantial survival benefit in third line surpasses
comparable standard-of-care overall survival of 5.8 months
- Median survival follow-up in third line was 10.6
months
- Treatment with THIO followed by Libtayo® has been generally
well-tolerated to date
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”,
the “Company”), a clinical-stage biopharmaceutical company
developing targeted immunotherapies for cancer, today announces
favorable interim survival benefit from its lead clinical candidate
THIO, a telomere-targeting treatment for patients with advanced
non-small cell lung cancer (NSCLC). A Phase 2 clinical trial,
THIO-101, is evaluating THIO sequenced with Regeneron’s immune
checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with
advanced NSCLC who failed two or more standard-of-care therapy
regimens.
Published available results suggest that overall survival (OS)
in third-line patients is 5.8 months.1
As of August 01, 2024, 16 patients had survival follow-up
surpassing 12 months, including 9 in third line treatment (3L).
Interim median survival follow-up in 3L was 10.6 months.
“THIO is showing a survival benefit for patients with advanced
NSCLC. As our follow-up continues, we have noted that three of the
earliest patients enrolled are approaching 17-month survival. We’re
on track to achieve our survival goals in third-line therapy,” said
Vlad Vitoc, M.D., Chairman and Chief Executive Officer of MAIA.
“THIO’s outperformance to date supports our thesis that our
telomere targeting agent could become a treatment option for people
suffering from advanced NSCLC.”
The 12-month survival data corresponds to the Company’s most
recent data from THIO-101 demonstrating favorable disease control
and overall response rates. As announced in April 2024, THIO 180mg
+ CPI in third-line treatment showed, in part, overall response
rate (ORR) of 38%, disease control rate (DCR) of 88% and median
progression-free survival (PFS) of 5.5 months.
MAIA expects to release full efficacy results of THIO-101 this
year.
About THIO
THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class
investigational telomere-targeting agent currently in clinical
development to evaluate its activity in Non-Small Cell Lung Cancer
(NSCLC). Telomeres, along with the enzyme telomerase, play a
fundamental role in the survival of cancer cells and their
resistance to current therapies. The modified nucleotide
6-thio-2’-deoxyguanosine (THIO) induces telomerase-dependent
telomeric DNA modification, DNA damage responses, and selective
cancer cell death. THIO-damaged telomeric fragments accumulate in
cytosolic micronuclei and activates both innate (cGAS/STING) and
adaptive (T-cell) immune responses. The sequential treatment with
THIO followed by PD-(L)1 inhibitors resulted in profound and
persistent tumor regression in advanced, in vivo cancer models by
induction of cancer type–specific immune memory. THIO is presently
developed as a second or later line of treatment for NSCLC for
patients that have progressed beyond the standard-of-care regimen
of existing checkpoint inhibitors.
About THIO-101, a Phase 2 Clinical Trial
THIO-101 is a multicenter, open-label, dose finding Phase 2
clinical trial. It is the first trial designed to evaluate THIO’s
anti-tumor activity when followed by PD-(L)1 inhibition. The trial
is testing the hypothesis that low doses of THIO administered prior
to cemiplimab (Libtayo®) will enhance and prolong immune response
in patients with advanced NSCLC who previously did not respond or
developed resistance and progressed after first-line treatment
regimen containing another checkpoint inhibitor. The trial design
has two primary objectives: (1) to evaluate the safety and
tolerability of THIO administered as an anticancer compound and a
priming immune activator (2) to assess the clinical efficacy of
THIO using Overall Response Rate (ORR) as the primary clinical
endpoint. Treatment with THIO followed by Regeneron’s cemiplimab
(Libtayo®) has been generally well-tolerated to date in a heavily
pre-treated population. For more information on this Phase II
trial, please visit ClinicalTrials.gov using the identifier
NCT05208944.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on
the development and commercialization of potential first-in-class
drugs with novel mechanisms of action that are intended to
meaningfully improve and extend the lives of people with cancer.
Our lead program is THIO, a potential first-in-class cancer
telomere targeting agent in clinical development for the treatment
of NSCLC patients with telomerase-positive cancer cells. For more
information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of
historical facts contained in this press release, are
forward-looking statements. Forward-looking statements are subject
to known and unknown risks, uncertainties, and other factors that
may cause our or our industry’s actual results, levels or activity,
performance or achievements to be materially different from those
anticipated by such statements. The use of words such as “may,”
“might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “project,” “intend,” “future,” “potential,”
or “continue,” and other similar expressions are intended to
identify forward looking statements. However, the absence of these
words does not mean that statements are not forward-looking. For
example, all statements we make regarding (i) the initiation,
timing, cost, progress and results of our preclinical and clinical
studies and our research and development programs, (ii) our ability
to advance product candidates into, and successfully complete,
clinical studies, (iii) the timing or likelihood of regulatory
filings and approvals, (iv) our ability to develop, manufacture and
commercialize our product candidates and to improve the
manufacturing process, (v) the rate and degree of market acceptance
of our product candidates, (vi) the size and growth potential of
the markets for our product candidates and our ability to serve
those markets, and (vii) our expectations regarding our ability to
obtain and maintain intellectual property protection for our
product candidates, are forward looking. All forward-looking
statements are based on current estimates, assumptions and
expectations by our management that, although we believe to be
reasonable, are inherently uncertain. Any forward-looking statement
expressing an expectation or belief as to future events is
expressed in good faith and believed to be reasonable at the time
such forward-looking statement is made. However, these statements
are not guarantees of future events and are subject to risks and
uncertainties and other factors beyond our control that may cause
actual results to differ materially from those expressed in any
forward-looking statement. Any forward-looking statement speaks
only as of the date on which it was made. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise, except as required by law. In this release, unless the
context requires otherwise, “MAIA,” “Company,” “we,” “our,” and
“us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
1 Girard N, et al. J Thorac Onc 2009;12:1544-1549.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240910368128/en/
Investor Relations Contact +1 (872) 270-3518
ir@maiabiotech.com
Maia Biotechnology (AMEX:MAIA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Maia Biotechnology (AMEX:MAIA)
Historical Stock Chart
From Sep 2023 to Sep 2024